Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) started the day on Wednesday, with a price increase of 6.17% at $20.98, before settling in for the price of $19.76 at the close. Taking a more long-term approach, ARCT posted a 52-week range of $17.52-$45.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 310.16%. Meanwhile, its Annual Earning per share during the time was 12.40%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -226.17%. This publicly-traded company’s shares outstanding now amounts to $26.83 million, simultaneously with a float of $24.70 million. The organization now has a market capitalization sitting at $567.30 million. At the time of writing, stock’s 50-day Moving Average stood at $21.40, while the 200-day Moving Average is $29.23.
Arcturus Therapeutics Holdings Inc (ARCT) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Arcturus Therapeutics Holdings Inc’s current insider ownership accounts for 8.68%, in contrast to 92.01% institutional ownership. According to the most recent insider trade that took place on Jun 12 ’24, this organization’s Chief Financial Officer sold 50,000 shares at the rate of 32.03, making the entire transaction reach 1,601,500 in total value, affecting insider ownership by 220,526. Preceding that transaction, on Jun 05 ’24, Company’s Chief Scientific Officer & COO sold 114 for 45.00, making the whole transaction’s value amount to 5,130. This particular insider is now the holder of 447,334 in total.
Arcturus Therapeutics Holdings Inc (ARCT) Earnings and Revenue Records
Arcturus Therapeutics Holdings Inc’s EPS decrease for this current 12-month fiscal period is -226.17% and is forecasted to reach -2.16 in the upcoming year.
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) Trading Performance Indicators
Let’s observe the current performance indicators for Arcturus Therapeutics Holdings Inc (ARCT). It’s Quick Ratio in the last reported quarter now stands at 3.78. The Stock has managed to achieve an average true range (ATR) of 1.27. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 3.78.
In the same vein, ARCT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.57, a figure that is expected to reach -1.22 in the next quarter, and analysts are predicting that it will be -2.16 at the market close of one year from today.
Technical Analysis of Arcturus Therapeutics Holdings Inc (ARCT)
If we take a close look at the recent performances of Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), its last 5-days Average volume was 0.37 million that shows plunge from its year to date volume of 0.49 million. During the previous 9 days, stock’s Stochastic %D was recorded 45.77% While, its Average True Range was 1.19.
Raw Stochastic average of Arcturus Therapeutics Holdings Inc (ARCT) in the period of the previous 100 days is set at 11.85%, which indicates a major fall in contrast to 69.32% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 53.98% that was lower than 86.61% volatility it exhibited in the past 100-days period.
